These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 766188)

  • 21. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI
    Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukemia in polycythemia vera. Relationship to splenic myeloid metaplasia and therapeutic radiation dose.
    Lawrence JH; Winchell HS; Donald WG
    Ann Intern Med; 1969 Apr; 70(4):763-71. PubMed ID: 5771533
    [No Abstract]   [Full Text] [Related]  

  • 23. Post-polycythemia myeloid metaplasia: experience with a large cohort of patients.
    Randi ML; Barbone E; Fabris F; Varotto L; Macri C; Girolami A
    J Med; 1994; 25(6):363-9. PubMed ID: 7769374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acute leukemia and primary Vaquez' polycythemia. 20 cases].
    Bernard JF; Renoux M; Dhermy D; Schneider M; Chouraqui F; Amar M; Boivin P
    Sem Hop; 1978 Sep 18-25; 54(25-28):797-804. PubMed ID: 214857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current management in polycythemia vera.
    Gilbert HS
    Semin Hematol; 2001 Jan; 38(1 Suppl 2):25-8. PubMed ID: 11242599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard.
    Toh BT; Gregory SA; Knospe WH
    Am J Hematol; 1988 May; 28(1):58-60. PubMed ID: 3369437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inter-relationship between polycythaemia vera, leukaemia and myeloid metaplasia.
    Modan B
    Clin Haematol; 1975 Jun; 4(2):427-39. PubMed ID: 1102196
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P).
    Randi ML; Fabris F; Varotto L; Rossi C; Macri C; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(3):461-7. PubMed ID: 1703118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].
    Bai J; Xue YP; Ye L; Yao JF; Zhou CL; Qian LS; Yang RC; Li HY; Zhang HY; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):685-8. PubMed ID: 18399175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 32P-therapy in polycythemia vera.
    Meuret G; Hoffmann G; Gmelin R
    Klin Wochenschr; 1975 Jun; 53(11):519-21. PubMed ID: 807769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival in a patient with polycythaemia vera for over thirty years: implications for treatment decisions in younger patients.
    Samuelsson J
    Leuk Lymphoma; 1998 Dec; 32(1-2):195-8. PubMed ID: 10037017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long remission in acute myeloblastic leukemia during Vaquez' polycythemia. Acute transformation of a myeloproliferative syndrome or successive neoplasms?].
    Dhermy D; Bernard JF; Renoux M; Boivin P
    Sem Hop; 1978 Sep 18-25; 54(25-28):814-7. PubMed ID: 214860
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use and risks of phosphorus-32 in the treatment of polycythaemia vera.
    Parmentier C
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1413-7. PubMed ID: 12955483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
    Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
    Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple myeloma on polycythemia vera following radioactive phosphorus therapy.
    West WO
    South Med J; 1976 Nov; 69(11):1516-7. PubMed ID: 1019658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Essential thrombocythemia following polycythemia vera: an unusual sequence.
    Randi ML; Barbone E; Zerbinati P; Soini B; Rossi C; Girolami A
    J Med; 1996; 27(5-6):363-8. PubMed ID: 9151204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.